Federal Cannabis Rescheduling: Evidence-Based Policy Over Celebrity Opinion
The debate over federal cannabis rescheduling requires evidence-based policy decisions rather than celebrity-driven discourse. Current Schedule I classification restricts vital clinical research and creates legal barriers that complicate patient access…
Legal Experts Caution Cannabis Industry on DEA Registration Following Medical … – Hemp Gazette
✦ New CED Clinical Relevance #63 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustryHempCBDTHCSafety Why This Matters Clinicians need to understand this regulatory distinction because…
In the Mix: 5 More Articles — May 25, 2026
The 2026 cannabis enforcement actions reveal ongoing raids and arrests impacting the cannabis industry. These enforcement efforts highlight the complex legal landscape clinicians face. Understanding 2026 cannabis enforcement actions is crucial for…
7 on 7: The biggest stories from last week you might’ve missed
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchMedical MarijuanaSchedulingHealthcareRegulationFederal Why This Matters # Clinical RelevanceThe…
Alabama Delays Automatic Medical Cannabis Rescheduling to Assess State Program Impact
✦ New CED Clinical Relevance #68 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyAnxietyPainMental HealthSafetyIndustryResearch Why This Matters Alabama’s delay in rescheduling medical…
Researchers Can Now Study State-Legal Medical Cannabis, But Hurdles Remain
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafetyPainAnxietyMental HealthNeurology Why This Matters Federal rescheduling of cannabis to Schedule…
In the Mix: Synthetic Cannabinoid Trafficking Update — May 21, 2026
This article reviews synthetic cannabinoid trafficking and its clinical impact in 2026. Synthetic cannabinoid trafficking poses unique risks compared to regulated cannabis. Clinicians should be aware of these developments for informed patient care.
More than 1,000 pounds of marijuana, 20 illegal firearms, 40 pounds of meth seized in …
✦ New CED Clinical Relevance #37 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyIndustryHempTHCCBDMental Health Clinical Summary This law enforcement operation highlights the ongoing…
Cannabis Rescheduling Arrives, With Limits: What The DOJ’s Final Order Does And Doesn’t Do
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchTHCCBDHempIndustrySafety Why This Matters Cannabis rescheduling to Schedule III will enable clinical…
Virginia Governor Signs Bill Establishing Resentencing Process for Felony Cannabis Convictions
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyMental HealthIndustrySafetyResearchAnxietyPain Why This Matters This resentencing law allows clinicians to…